Therapie des Typ-2-Diabetes

Rüdiger Landgraf; Jens Aberle; Andreas L. Birkenfeld; Baptist Gallwitz; Monika Kellerer; Harald H. Klein; Dirk Müller-Wieland; Michael A. Nauck; Tobias Wiesner; Erhard Siegel

doi:10.1055/a-1394-2313

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2021; 16(S 02): S168-S206
DOI: 10.1055/a-1394-2313

DDG-Praxisempfehlung

Therapie des Typ-2-Diabetes

Rüdiger Landgraf

¹Deutsche Diabetes Stiftung, Düsseldorf

,

Jens Aberle

²Sektion Endokrinologie und Diabetologie, Universitäres Adipositas-Zentrum Hamburg, Universitätsklinikum Hamburg-Eppendorf

,

Andreas L. Birkenfeld

³Deutsches Zentrum für Diabetesforschung (DZD e. V.), Neuherberg

,

Baptist Gallwitz

⁴Medizinische Klinik IV, Diabetologie, Endokrinologie, Nephrologie, Universitätsklinikum Tübingen

,

Monika Kellerer

⁵Zentrum für Innere Medizin I, Marienhospital Stuttgart

,

Harald H. Klein

⁶Medizinische Klinik I, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum

,

Dirk Müller-Wieland

⁷Medizinische Klinik I, Universitätsklinikum RWTH Aachen, Aachen

,

Michael A. Nauck

⁸Diabeteszentrum Bochum-Hattingen, St.-Josef-Hospital, Ruhr-Universität, Bochum

,

Tobias Wiesner

⁹MVZ Stoffwechselmedizin Leipzig, Leipzig

,

Erhard Siegel

¹⁰Abteilung für Innere Medizin – Gastroenterologie, Diabetologie/Endokrinologie und Ernährungsmedizin, St. Josefkrankenhaus Heidelberg GmbH, Heidelberg

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Nationale VersorgungsLeitlinien. NVL-2-Diabetes – Teilpublikation. 2. Auflage. www.leitlinien.de/themen/diabetes
2 Alberti KGMM, Eckel RH, Grundy SM. et al. Harmonizing the Metabolic Syndrome. Circulation 2009; 120: 1640-1645
3 Elwyn G, Vermunt NPCA. Goal-based shared decision-making: developing an integrated model. Journal of Patient Experience 2019; 1-9
4 Wang R, Song Y, Yan Y. et al. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. Atherosclerosis 2016; 254: 193-199
5 Parhofer KG, Birkenfeld AL, Krone W. et al. Lipidtherapie bei Patienten mit Diabetes mellitus. Diabetologie 2020; 15 (Suppl. 01) S160-S165
6 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41 (01) 111-188
7 The Task Force for the management of arterial hypertension of the European Society of cardiology (ESC) and the European Society of Hypertension (ESH). 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104
8 Heinemann L, Kaiser P, Freckmann G. et al. HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose?. Diabetologie 2018; 13: 46-53
9 Landgraf R, Nauck M, Freckmann G. et al. Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen?. Dtsch Med Wochenschr 2018; 143: 1549-1555
10 Nauck M, Gerdes C, Petersmann A. et al. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Update 2020. Diabetologie 2020; 15 (Suppl. 01) S9-S17
11 Landgraf R. HbA1c in der Diabetesdiagnostik. Der Goldstandard?. Diabetes aktuell 2021; 19: 22-29
12 Ahlqvist E, Storm P, Käräjämäki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018; 6 (05) 361-369
13 Zaharia OP, Strassburger K, Strom A. German Diabetes Study Group. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7 (09) 684-694
14 Dennis JM, Shields BM, Henley WE. et al. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 2019; 7 (06) 442-451
15 Zhang Y, Pan XF, Chen J. et al. Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Diabetologia 2020; 63: 21-3316
16 Nationale VersorgungsLeitlinie (NVL) Diabetes – Strukturierte Schulungsprogramme. 2018 www.leitlinien.de/nvl/diabetes/schulungsprogramme
17 Forouhi NG, Misra A, Mohan V. et al. Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ 2018; 361: k2234
18 Serra-Majem L, Román-Viñas B, Sanchez-Villegas A. et al. Benefits of the Mediterranean diet: Epidemiological and molecular aspects. Mol Aspects Med 2019; 67: 1-55
19 Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol 2019. doi:S2213-8587(19)30076-2
20 Evert AB, Dennison M, Gardner CD. et al. Nutrition therapy for adults with Diabetes or prediabetes: a consensus report. Diabetes Care 2019; 42 (05) 731-754
21 Hauner H. Evidenz in der Ernährungstherapie des Diabetes mellitus. Diabetologe 2021; published online 29.06.2021
22 Chester B, Babu JR, Greene MW. et al. The effects of popular diets on type 2 diabetes management. Diabetes Metab Res Rev 2019; 35: e3188
23 Kempf K, Altpeter B, Berger J. et al. Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: A randomized controlled trial. Diabetes Care 2017; 40 (07) 863-871
24 Lean MEJ, Leslie WS, Barnes AC. et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomized trial. Lancet Diabetes Endocrinol 2019; 7: 344-355
25 Adipositas – Prävention und Therapie. AWMF-Register Nr. 050-001.
26 Aberle J, Lautenbach A, Meyhöfer S. et al. Adipositas und Diabetes. Diabetologe 2021; 16 (Suppl. 02) S290-S298
27 Yang D, Yang Y, Li Y. et al. Physical exercise as therapy for type 2 diabetes mellitus: from mechanism to orientation. Ann Nutr Metab 2019; 74 (04) 313-321
28 Tarp J, Støle AP, Blond K. et al. Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetologia 2019; 62: 1129-1142
29 Liu Y, Ye W, Chen Q. et al. Resistance exercise intensity is correlated with attenuation of HbA1c and insulin in patients with type 2 diabetes: A systematic review and meta-analysis. Int J Environ Res Public Health 2019; 16 (01) 140
30 Esefeld K, Kress S, Behrens M. et al. Diabetes, Sport und Bewegung. Diabetologe 2021; 16 (Suppl. 02) S299-S307
31 Piercy KL, Richard P, Troiano RP. et al. The physical activity guidelines for Americans. JAMA 2018; 320 (19) 2020-2028
32 Jabardo-Camprubí G, Donat-Roca R, Sitjà-Rabert M. et al. Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: A systematic review and meta-analysis. Physiol Behav 2020; 215: 112786
33 Kar D, Gillies C, Nath M. et al. Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetologica 2019; 56: 839-850
34 Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung. S3-Leitlinie Langversion AWMF-Register Nr. 076-006.
35 Tabakatlas Deutschland 2020. www.dkfz.de/de/tabakkontrolle/download/Publikationen/sonstVeroeffentlichungen/Tabakatlas-Deutschland-2020_dp.pdf ; Seiten 38–39 und 110–111
36 Fleming GA, Petrie JR, Bergenstal RM. et al. Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care 2020; 43 (01) 250-260
37 Khunti K, Gomes MB, Pocock S. et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes Obes Metab 2018; 20: 427-437
38 Matthews DR, Paldánius PM, Proot P. VERIFY study group. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 2019; 394: 1519-1529
39 Gough SC, Bode B, Woo V. et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabet Endocrinol 2014; 2 (11) 885-893
40 Diamant M, Nauck MA, Shaginian R. et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014; 37 (10) 2763-2773
41 Ahmann A, Rodbard HW, Rosenstock J. et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo controlled trial. Diabetes Obes Metab 2015; 17: 1056-1064
42 Montvida O, Klein K, Kumar S. et al. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes Obes Metab 2017; 19 (01) 108-117
43 Billings LK, Doshi A, Gouet D. et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The DUAL VII randomized clinical trial. Diabetes Care 2018; 41 (05) 1009-1016
44 Parhofer KG. Lipidtherapie. Diabetologe 2021; 16 (Suppl. 02) S312-S317
45 Mengden T, Weisser B. Therapieüberwachung bei arterieller Hypertonie. Dtsch Ärztebl 2021; 118 (27) 473-478
46 Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter. 2018 www.leitlinien.de/nvl/diabetes/nierenerkrankungen
47 ESC/ESH Guidelines 2018. Management der arteriellen Hypertonie. www.dgk.de; www.hochdruckliga.de
48 American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2021. Diabetes Care 2021; 44 (Suppl. 01) S125-S150
49 The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-2116
50 Banegas JR, Ruilope LM, de la Sierra A. et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 2018; 378: 1509-1520